林媛 - 中国医学科学院药物研究所 -

个人简介

教育背景 2008.09-2012.07 北京协和医学院，微生物与生化药学专业，医学博士 2005.09-2008.07 四川大学华西医学中心，病原生物学专业，医学硕士 2000.09-2005.07 山西医科大学，临床医学专业，医学学士工作经历 2015.09-至今中国医学科学院药物研究所，药理室，副研究员 2012.09-2015.08 中国医学科学院药物研究所，药理室，助理研究员

研究领域

主要从事抗感染药理学与新药发现研究。研究方向包括新型抗结核、抗革兰氏阴性菌、抗病毒药物的发现以及药物作用新分子机制研究等。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Lin Y*, Zhang H*, Zhu N, Wang X, Han Y, Chen M, Jiang J#, Si S#. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity. Tuberculosis (Edinb). 2018; 110: 79-85. 2. Lin Y, Li Y, Zhu N, Han Y, Jiang W, Wang Y, Si S#, Jiang J#. The antituberculosis antibiotic capreomycin inhibits protein synthesis by disrupting interaction between ribosomal proteins L12 and L10. Antimicrob Agents Chemother. 2014; 58(4): 2038-2044. 3. Lin Y, Zhu N, Han Y, Jiang J#, Si S#. Identification of anti-tuberculosis agents that target the cell-division protein FtsZ. J Antibiot (Tokyo), 2014; 67(9): 671-676. 4. Lin Y*, Li Y*, Zhu Y, Zhang J, Li Y, Liu X, Jiang W, Yu S, You XF, Xiao C, Hong B, Wang Y#, Jiang JD#, Si S#. Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system. Proc Natl Acad Sci USA. 2012; 109(43): 17412-17417. 5. Lin Y, Chen S, Si S#, Xie Y#. Expression, purification, crystallization and preliminary X-ray crystallographic analysis of the hyperthermophilic nucleotidyltransferase TTHA1015 from Thermus thermophilus HB8. Acta Cryst. 2011; F67, 235-237. 6. Zhu N*, Lin Y*, Li D, Gao N, Liu C, You X, Jiang J, Jiang W#, Si S#. Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase. J Antimicrob Chemother. 2015; 70(8): 2287-2294. 7. Zhu Y*, Lin Y*, Liu X, Hu W#, Wang Y#. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition. Biochem Biophys Res Commun. 2017; 483(1): 495-501. 8. Zhu Y, Lin Y, Liu A, Shui M, Li R, Liu X, Hu W, Wang Y. Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors. Biochem Pharmacol. 2015; 95(4): 253-262. 9. Zhu N, Wang X, Li D, Lin Y, You X, Jiang J, Xu Y, Jiang W, Si S. IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis. Sci Rep. 2018; 8: 17439. 10. Li D, Gao N, Zhu N, Lin Y, Li Y, Chen M, You X, Lu Y, Wan K, Jiang JD, Jiang W, Si S. Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB. Bioorg Med Chem Lett. 2015; 25(22): 5178-5181. 11. Zhu Y, Li R, Lin Y, Shui M, Liu X, Chen H, Wang Y. Engineering Factor Xa inhibitor with multiple platelet-binding sites facilitates its platelet targeting. Sci Rep. 2016; 6: 29895. 12. Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, Lin Y, Chen Y, You XF, Wang Y, Jiang JD. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015; 5: 12155. 13. Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017; 70: 72-84. 14. Li N, Wang X, Xu Y, Lin Y, Zhu N, Liu P, Lu D, Si S. Identification of a novel liver X receptor agonist that regulates the expression of key cholesterol homeostasis genes with distinct pharmacological characteristics. Mol Pharmacol. 2017; 91(4): 264-276. 15. Wang Y, Tong Q, Shou JW, Zhao ZX, Li XY, Zhang XF, Ma SR, He CY, Lin Y, Wen BY, Guo F, Fu J, Jiang JD. Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine. Theranostics. 2017; 24(9): 2443-2451. 16. 林媛，张红娟，韩燕星，蒋建东。小檗碱对肠道菌的抑制作用。中国医药生物技术，2018，13(4)：335-338. 17. 林媛，司书毅，蒋建东。小檗碱的抗菌作用。药学学报，2018，53(2)：163-168. 18. 林媛，朱宁屿，蒋建东，司书毅。以FtsZ为靶点的抗结核药物筛选模型的建立及应用。中国抗生素杂志，2015，40(3)，166-170. 19. 林媛，朱宁屿，蒋建东，司书毅。靶向FtsZ先导化合物的筛选及其抗结核作用探讨。中国新药杂志，2015，24(5)，592-594. 20. 林媛，朱宁屿，蒋建东，司书毅。结核分枝杆菌FtsZ抑制剂的筛选和活性研究。中国医药生物技术，2015，10(2)，109-112.